BD announced its board of directors has unanimously authorized BD management to pursue a plan to separate BD’s Biosciences and Diagnostic Solutions business from the rest of BD to enhance ...

Becton, Dickinson and Company (BDX, Financials) announced a major strategic shift with plans to separate its Biosciences and Diagnostic Solutions unit, aiming to create two independent ...

Good day, everyone. Welcome to today's Conference Call to discuss BD's First Quarter Fiscal 2025 Earnings and BD's announcement of its Intent to Separate BD's Biosciences and Diagnostic Solutions ...

American medical technology (MedTech) company Becton Dickinson (BDX) plans to split from its bioscience and diagnostic solutions arms to become a leaner and more focused company. The news was anno ...

Revenue: US$5.17b (up 9.8% from 1Q 2024). Net income: US$303.0m (up 7.8% from 1Q 2024). Profit margin: 5.9% (down from 6.0% in 1Q 2024). EPS: US$1.05 (up from US$0.97 in 1Q 2024). Revenue exceeded ...

Becton Dickinson plans to separate its Biosciences and Diagnostic Solutions unit, aiming for completion by fiscal 2026. BD reported Q1 2025 sales of $5.17B, up 9.8% YoY, beating estimates.

Becton Dickinson BDX0.80%increase; green up pointing triangle and Co. said it plans to break off its bioscience and diagnostic solutions business to focus on medical technology. Chief Executive ...

Becton Dickinson shares have climbed 8% since the beginning of the year, while the S&P’s 500 index has increased 27%. In the final minutes of trading on Wednesday, shares hit $245.06, a rise of ...

Becton Dickinson and Co. said it plans to break off its bioscience and diagnostic solutions business to focus on medical technology. Chief Executive Tom Polen said he believes the separation would ...

Becton Dickinson's announcement of a separation of its biosciences and diagnostics solutions business overshadows mediocre performance of the core business. Shares are slightly down on the news.